Enhancing therapeutic efficacy of the MEK inhibitor, MEK162, by blocking autophagy or inhibiting PI3K/Akt signaling in human lung cancer cells

Autophagy in the Pathogenesis of Disease

Beth Levine, Guido Kroemer · Cell · 2008 · 7K citations · Full text

Life Sciences, Cell Biology, Pathobiology +10

RAS/ERK Signaling Promotes Site-specific Ribosomal Protein S6 Phosphorylation via RSK and Stimulates Cap-dependent Translation

Philippe P. Roux, David Shahbazian, Hieu Vu et al. · Journal of Biological Chemistry · 2007 · 758 citations · Full text

Life Sciences, Biochemistry, Molecular Biology +12

Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study

Pasi A. Jänne, Alice T. Shaw, José Rodrigues Pereira et al. · The Lancet Oncology · 2012 · 657 citations

Medicine, Oncology, Pharmacology +11

MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study

Paolo A. Ascierto, Dirk Schadendorf, Carola Berking et al. · The Lancet Oncology · 2013 · 644 citations

Veterinary Medicine, Biomedical Sciences, Oncology +13

MEK Inhibition Leads to PI3K/AKT Activation by Relieving a Negative Feedback on ERBB Receptors

Alexa B. Turke, Youngchul Song, Carlotta Costa et al. · Cancer Research · 2012 · 364 citations · Full text

Life Sciences, Molecular Biology, Oncology +17